<DOC>
	<DOCNO>NCT01549951</DOCNO>
	<brief_summary>The purpose phase 2 , open-label , single-arm , multidose , multicenter study investigate effect Orteronel plus Prednisone QT/QTc interval patient Metastatic Castration-Resistant Prostrate Cancer</brief_summary>
	<brief_title>Study Investigate Effects Orteronel QT/QTc Interval Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Voluntary write consent Screening PSA â‰¥ 2ng/ml Patients must diagnosis mCRPC Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prior surgical medical castration testosterone screen &lt; 50 ng/dL Prior chemotherapy prostate cancer within 6 month prior screen . ( Any prior therapy cabazitaxel , mitoxantrone , anthracyclines exclusionary . ) Documented central nervous system metastases Clinically significant heart disease Patients abnormal 12lead ECG result screen include one following : QRS &gt; 110 m , QTcF &gt; 480ms , PR interval &gt; 200 m Patients history risk factor TdP include unexplained syncope , know long QT syndrome , heart failure , angina , clinically significant abnormal laboratory assessment Please note additional inclusion exclusion criterion . The study center determine meet criterion . Site personnel explain trial detail answer question may qualify study . You decide whether wish participate . If qualify trial , site personnel explain reason</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Metastatic castrate resistant prostate cancer , mCRPC , orteronel , TAK-700 , Phase 2 , QT , QTc</keyword>
</DOC>